RNA therapeutic for targeted SPP1 inhibition in tumor-associated myeloid cells
A novel RNA therapeutic utilizing lipid nanoparticles for precision inhibition of SPP1 in tumor-associated myeloid cells, aiming to reprogram these cells and boost anti-tumor immunity by enhancing T cell infiltration and activation.
Overview
This innovative RNA therapeutic is designed to precisely target and inhibit Secreted Phosphoprotein 1 (SPP1) within tumor-associated myeloid cells (TAMCs), such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). By employing lipid nanoparticle-based delivery, the therapy aims to reprogram these immunosuppressive cells, enhancing their ability to present antigens and elicit a robust anti-tumor response. The approach has shown promise in increasing the phagocytosis of tumor cells and promoting T cell activation and infiltration, which are crucial for effective tumor killing.
Technical specifications
- Target: Secreted Phosphoprotein 1 (SPP1) in TAMCs
- Delivery Method: Lipid nanoparticle-based RNA therapeutic
- Mechanism: Inhibits SPP1 to enhance TAMC phagocytosis and antigen presentation
- Effect: Reprograms TAMCs to pro-inflammatory effectors, activating T cells
- Validation: RNA sequencing and immune profiling confirm reprogramming effects
Technology readiness level
Currently, the technology is at TRL 4, having been validated in a laboratory setting. Further validation is planned using animal models to assess the therapeutic's impact on TAMC functionality, T cell behavior, and overall anti-tumor efficacy. Additional studies will explore the reshaping of the tumor microenvironment, with the goal of advancing to higher readiness levels.
About Northwestern University
Northwestern University is a comprehensive private research university with campuses in Evanston and downtown Chicago and a collaborative, cross‑disciplinary culture. Integration with a major hospital system enables clinical research, diverse patient access, and rapid translation from bench to bedside. Shared research cores, prototyping facilities, a campus incubator, and dedicated corporate engagement teams make it straightforward to scope projects, structure agreements, and place talent. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, complemented by foundation and industry partnerships. A dedicated technology transfer office advances IP strategy, licensing, and startup formation.
Inquire about this partnering listing
Industry applications
delivered to your inbox.